ASH 2024 | Outcomes of teclistamab in RRMM with prior exposure to BCMA-directed therapy

We’ve been lucky in multiple myeloma to have many agents that really work for our patients. And you know, a novel class of agents has been BCMA-targeted therapies, including CAR T-cell therapy and bispecific antibodies. And so now what we’re trying to figure out is how do we sequence all these therapies that we have, how to optimize the response and you know, how to sequence them. And so we looked at close to 200 patients across the nation who received teclistamab, which is a BCMA-directed bispecific antibody. And these patients who got teclistamab had received prior BCMA therapy, either CAR-T cell therapy, antibody drug conjugates, or different bispecific antibodies. And so we looked at how these patients responded to teclistamab after having had prior BCMA-targeted therapy. What we found was the patients actually had lower response rates to teclistamab after prior BCMA-targeted therapy, so 51% versus 61% for patients who are BCMA naive, so no BCMA-targeted therapy at all. And the patients did have, did show a trend towards worsening of PFS. So patients who received prior BCMA-targeted therapy and then got teclistamab, their progression-free survival was shorter actually. Another thing that we found was that if you actually wait more than nine months from prior BCMA-targeted therapy and then you give teclistamab nine months after that, that actually can help your patients respond better. And so the optimal time cutoff for patients, if you’re thinking about sequencing BCMA-targeted therapies, waiting nine months actually would probably help kind of get better responses and potentially better progression-free survival for patients with teclistamab.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.